Mitsuo Motobayashi

Dr. Mitsuo Motobayashi

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2019 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
TYTomomi Yamaguchi
Tomomi Yamaguchi
KTKyoko Takano
Kyoko Takano
YIYuji Inaba
Yuji Inaba
MMManami Morikawa
Manami Morikawa
MMMitsuo Motobayashi
Mitsuo Motobayashi
Tomoki KoshoTomoki Kosho
Tomoki Kosho

1 October 2017 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
KTKyoko Takano
Kyoko Takano
KGKazuya Goto
Kazuya Goto
MMMitsuo Motobayashi
Mitsuo Motobayashi
KWKeiko Wakui
Keiko Wakui
RKRie Kawamura
Rie Kawamura
TKTomoki Kosho
Tomoki Kosho

1 April 2015 in Pediatric Neurology
Verified
Journal Article
Open access
MMMitsuo Motobayashi
Mitsuo Motobayashi
YIYuji Inaba
Yuji Inaba
TNTakafumi Nishimura
Takafumi Nishimura
NKNorimoto Kobayashi
Norimoto Kobayashi
YNYozo Nakazawa
Yozo Nakazawa
KKKenichi Koike
Kenichi Koike
Myasthenia gravis is a B cell-mediated autoimmune disorder. The pathophysiology of childhood-onset ocular myasthenia gravis remains unclear. We investigated serum B cell-activating factor levels and other immunological parameters in child patients with ocular myasthenia gravis. Blood samples were obtained from 9 children with ocular myasthenia gravis and 20 age-matched controls. We assayed serum concentrations of B cell-activating factor, anti-acetylcholine receptor antibody titers, 7 types of cytokines (interleukins-2, -4, -6, -10, and -17A; interferon-γ; tumor necrosis factor-α) as well as the percentages of peripheral blood CD4+, CD8+, and CD19+ cells. Serum B cell-activating factor levels were significantly higher before immunosuppressive therapy in patients with childhood-onset ocular myasthenia gravis than in controls and decreased after immunosuppressive therapy. A significant positive correlation was observed between serum B cell-activating factor levels and anti-acetylcholine receptor antibody titers in patients with myasthenia gravis. Serum B cell-activating factor concentrations did not correlate with the percentages of CD4+, CD8+, and CD19+ cells or the CD4+/CD8+ ratio. No significant differences were observed in the levels of the 7 different types of cytokines examined, including interleukin-17A, between preimmunosuppressive therapy myasthenia gravis patients and controls. Circulating B cell-activating factor may play a key role in the pathophysiology of childhood-onset ocular myasthenia gravis.

1 October 2017 in Brain and Development
Verified
Journal Article
Closed access
MMManami Morikawa
Manami Morikawa
KTKyoko Takano
Kyoko Takano
MMMitsuo Motobayashi
Mitsuo Motobayashi
NSNaoko Shiba
Naoko Shiba
TKTomoki Kosho
Tomoki Kosho
YIYuji Inaba
Yuji Inaba

18 February 2014 in Brain and Development
Verified
Journal Article
Closed access
PDF file
MMMitsuo Motobayashi
Mitsuo Motobayashi
YIYuji Inaba
Yuji Inaba
TFTetsuhiro Fukuyama
Tetsuhiro Fukuyama
TKTakashi Kurata
Takashi Kurata
TNTaemi Niimi
Taemi Niimi
KKKenichi Koike
Kenichi Koike

19 December 2023 in Brain and Development
Verified
Journal Article
Closed access
MNMakoto Nishioka
Makoto Nishioka
MMMitsuo Motobayashi
Mitsuo Motobayashi
TFTetsuhiro Fukuyama
Tetsuhiro Fukuyama
YIYuji Inaba
Yuji Inaba